Evaxion Receives Positive Feedback on Patent Application for AI-Based Novel Cancer Vaccine Target Identification Method
Evaxion Biotech announced positive feedback from an International Preliminary Report on Patentability (IPRP) for its AI-based method to identify novel cancer vaccine targets. This patent application (PCT/EP2022/086444) involves a unique approach to recognizing tumor vaccine targets derived from Endogenous Retroviruses (ERVs) using their proprietary AI-Immunology™ platform.
The feedback underscores the novelty and inventiveness of Evaxion's claims, enhancing the company's position in the personalized cancer vaccine field. The endorsement by the World Intellectual Property Organization (WIPO) confirms the patent's promising prospects. CEO Christian Kanstrup emphasized the importance of this validation in advancing Evaxion's innovative cancer treatments and strengthening their intellectual property portfolio as part of a multi-partner strategy.
- Received positive feedback from an International Preliminary Report on Patentability (IPRP).
- The report indicates promising prospects for granted patents and protecting the invention.
- The feedback highlights the novelty and inventiveness of Evaxion's personalized cancer vaccine targets derived from Endogenous Retroviruses (ERVs).
- Strengthens Evaxion’s position in the personalized cancer vaccine field.
- None.
Evaxion's patent application for a novel cancer vaccine target identification method using AI represents a significant advancement in personalized medicine. A standout point is the use of Endogenous Retroviruses (ERVs) as targets, which could open new therapeutic avenues. The AI-Immunology™ platform's ability to identify these targets could enhance the precision and efficacy of cancer vaccines. This innovation places Evaxion at the cutting edge of both AI and biotech sectors, underscoring the potential for technology to revolutionize healthcare.
From a technological perspective, the feedback on the patent application indicates that Evaxion is successfully merging AI capabilities with medical research, offering a competitive advantage. This could potentially lead to faster, more effective development cycles for new treatments, with AI streamlining the identification process, saving time and resources. However, it is important to monitor how the technology performs in clinical settings and its acceptance within the medical community.
The positive feedback on Evaxion's patentability report signals a strong market position for the company in the personalized cancer vaccine market. The validation from the World Intellectual Property Organization enhances Evaxion's intellectual property portfolio, important for safeguarding proprietary technology and maintaining a competitive edge. This recognition could attract potential partnerships and investors, bolstering confidence in Evaxion's innovative approach.
Furthermore, the expansion of its personalized vaccines into a broader cancer patient population could increase market demand. Investors should consider the long-term growth prospects of Evaxion, as securing strong patents is a critical step in the commercialization process. However, it is also necessary to be aware of the inherent risks in the biotech sector, such as regulatory hurdles and the need for successful clinical trials.
- Positive Feedback Received: An International Preliminary Report on Patentability (IPRP) indicates promising prospects for obtaining granted patents and protecting the invention
- Unique Attributes and Inventiveness: The feedback highlights the distinct and inventive nature of all relevant claims in the application, distinguishing the invention in the field of personalized cancer vaccines
- Strengthened Position: The patentability report reinforces Evaxion’s strong stance in the personalized cancer vaccines field and underlines the Company’s innovative approach
COPENHAGEN, Denmark, June 26, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, receives positive feedback on its recent patent application for a new type of personalized vaccine targets, underscoring its novelty and inventiveness.
The patent application PCT/EP2022/086444 discloses a method for identifying a novel category of tumor vaccine targets derived from Endogenous Retroviruses (ERVs) using Evaxion’s core platform AI-Immunology™. With this invention, Evaxion has tapped into a new source of cancer-specific targets, allowing the expansion of its personalized vaccines into a broader population of cancer patients.
“We are thrilled with the recent positive feedback provided in the patentability report, confirming novelty and inventive step for all relevant claims in our personalized ERV-based vaccine. This endorsement from the World Intellectual Property Organization underscores Evaxion's commitment to advancements in cancer treatment through innovation and reinforces our position at the forefront of the personalized cancer vaccine field. Establishing the strongest possible intellectual property portfolio around our inventions is an important element in our multi-partner strategy. We remain committed to advancing our AI-Immunology™ platform and bringing cutting-edge solutions to patients with high unmet medical needs,” said Christian Kanstrup, CEO at Evaxion.
About ERVs
ERVs are remnants of ancient viruses lying dormant in our genome. ERVs are often overexpressed in cancer but not in healthy tissue, making them visible to the immune system and hence promising targets for cancer vaccines. AI-Immunology™ is crucial in allowing the identification of therapeutically relevant ERV tumor antigens from genomic patient tumor data.
About EVAXION
Evaxion Biotech A/S is a pioneering TechBio company based upon its AI platform, AI-Immunology™. Evaxion’s proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Based upon AI-Immunology™, Evaxion has developed a clinical-stage oncology pipeline of novel personalized vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. Evaxion is committed to transforming patients’ lives by providing innovative and targeted treatment options. For more information about Evaxion and its groundbreaking AI-Immunology™ platform and vaccine pipeline, please visit our website.
Forward-Looking Statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,” “continue,” “estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could,” and other words and terms of similar meaning identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares, the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our business from the worldwide ongoing COVID-19 pandemic and the ongoing conflict in the region surrounding Ukraine and Russia and the Middle East; and other uncertainties affecting our business operations and financial condition. For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. We do not assume any obligation to update any forward-looking statements except as required by law.
FAQ
What patent feedback did Evaxion receive for its AI-based cancer vaccine method?
How does Evaxion's new method identify cancer vaccine targets?
What is the significance of the IPRP feedback for Evaxion?
What is the potential impact of the patent on Evaxion's stock (EVAX)?
